The continuous emergence of severe acute respiratory coronavirus 2 (SARS-CoV-2) variants and the increasing number of breakthrough infection cases among vaccinated people support the urgent need for research and development of antiviral drugs. Viral entry is an intriguing target for antiviral drug development. We found that diltiazem, a blocker of the L-type calcium channel Ca(v)1.2 pore-forming subunit (Ca(v)1.2 α(1c)) and an FDA-approved drug, inhibits the binding and internalization of SARS-CoV-2, and decreases SARS-CoV-2 infection in cells and mouse lung. Ca(v)1.2 α(1c) interacts with SARS-CoV-2 spike protein and ACE2, and affects the attachment and internalization of SARS-CoV-2. Our finding suggests that diltiazem has potential as a drug against SARS-CoV-2 infection and that Ca(v)1.2 α(1c) is a promising target for antiviral drug development for COVID-19.
Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung